Topics

Glioblastoma | Treatment | Chemotherapy | Irinotecan

Home > Publications > Topics > Glioblastoma > Treatment > Chemotherapy > Irinotecan

McConville C, Lastakchi S, Al Amri A, Ngoga D, Fayeye O, Cruickshank G.
Local Delivery of Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of Administration.
Cancers (Basel). 2024 Aug 29;16(17):3008. doi: 10.3390/cancers16173008. PMID: 39272866. Observational study. ˍ

Falcón A, Ponce S, Cote GM, Gil A, Lin JJ, Bockorny B, Martínez J, Kahatt C, Martinez S, Zubiaur P, Siguero M, Cullell-Young M, Jiménez J, Zugazagoitia J, Paz-Ares L.
Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors.
Invest New Drugs. 2025 Sep 18. doi: 10.1007/s10637-025-01583-y. PMID: 40963055. Interventional study. ˍ

Hsu CY, Baig MR, Patel PN, Singh G, Abdelrahim IM, Kadhem M, Arora V, Maddula VR, Nayak PP, Iqbal MS.
Innovative approaches to irinotecan-based therapies for glioblastoma: Advancements in drug delivery and combination strategies.
Crit Rev Oncol Hematol. 2026 Jan 22;219:105144. doi: 10.1016/j.critrevonc.2026.105144. PMID: 41580174. Review˰ ˍ